Physician profile
Lynn Polonski
NPI 1871674507
$8,916.10
in general payments reported to CMS, 2019-2025
33 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $683 · 2021: $1,027 · 2022: $949 · 2023: $1,745 · 2024: $1,309 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,731.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,457.99 | 2019-2025 | Idose, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $1,003.80 | 2019-2025 | Clareon, Clareon Panoptix Pro, Acrysof Iq Panoptix Uv Iol |
| Novartis Pharmaceuticals Corporation | $887.85 | 2019-2023 | |
| Amgen INC. | $569.70 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $426.22 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Horizon Therapeutics Plc | $420.00 | 2019-2023 | Tepezza |
| Rxsight INC | $417.39 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Kala Pharmaceuticals, INC. | $366.20 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $253.11 | 2020-2024 | Cequa |
| Depuy Synthes Sales INC. | $223.49 | 2021-2025 | Na, Matrixmidface |
| Mallinckrodt Hospital Products INC. | $217.72 | 2024-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $214.56 | 2019-2021 | |
| Dompe US, INC. | $205.62 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $201.49 | 2022-2025 | Miebo, Vyzulta, Envista Envy Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $191.83 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $155.07 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Lumenis Be INC | $128.96 | 2023 | M22 |
| Mallinckrodt Enterprises LLC | $73.71 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $66.20 | 2024-2025 | Xdemvy |
| Allergan, INC. | $64.82 | 2020-2022 | |
| Stryker Corporation | $62.57 | 2025 | Medpor Titan |
| Kls-Martin L.P. | $45.93 | 2023-2024 | |
| Akorn Operating Company LLC | $42.97 | 2021 | |
| Ocular Therapeutix, INC. | $37.78 | 2020-2023 | Dextenza |
| Rayner Intraocular Lenses Limited | $30.17 | 2025 | Omidria |
| Harrow Eye, LLC | $28.08 | 2025 | Vevye |
| Thea Pharma INC. | $22.52 | 2023 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abbvie INC. | $18.73 | 2023 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Sight Sciences, INC. | $16.19 | 2021 | |
| Shire North American Group INC | $14.40 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Polonski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.